📗 Cite This Artifact
Lecanemab CLARITY-AD Trial
Overview
CLARITY-AD (NCT03887455) was a landmark Phase 3 randomized, double-blind, placebo-controlled trial evaluating lecanemab (Leqembi) in early Alzheimer's disease patients. The trial met its primary endpoint, demonstrating statistically significant slowing of cognitive decline and represents the first Phase 3 trial of an anti-amyloid antibody to show clear clinical benefit in early AD[@lecanemab2023].
Lecanemab received accelerated approval from the FDA in January 2023 based on the CLARITY-AD results, making it the first amyloid-targeting therapy to demonstrate meaningful clinical efficacy in a Phase 3 trial.
Trial Details
| Parameter | Value |
|-----------|-------|
| NCT Number | NCT03887455 |
| Phase | Phase 3 |
| Status | Completed |
| Sponsor | Eisai Co., Ltd. |
| Collaborator | Biogen |
| Enrollment | 1,795 patients |
| Duration | 18 months |
| Location | Multiple countries worldwide |
| Drug | Lecanemab (Leqembi) |
| Dosage | 10 mg/kg biweekly IV infusion |
Mechanism of Action
Lecanemab is a monoclonal antibody that selectively binds to and clears soluble amyloid-beta (Aβ) protofibrils, which are believed to be the most toxic form of amyloid plaques in Alzheimer's disease[@lecanemab2023].
Target Specificity
- Primary Target: Aβ protofibrils (soluble oligomeric species)
- Epitope: 3X42 region of Aβ
- Selectivity: 100-fold greater affinity for protofibrils vs monomers
- Mechanism: Fc-mediated microglial phagocytosis
Amyloid Clearance Pathway
...
Overview
CLARITY-AD (NCT03887455) was a landmark Phase 3 randomized, double-blind, placebo-controlled trial evaluating lecanemab (Leqembi) in early Alzheimer's disease patients. The trial met its primary endpoint, demonstrating statistically significant slowing of cognitive decline and represents the first Phase 3 trial of an anti-amyloid antibody to show clear clinical benefit in early AD[@lecanemab2023].
Lecanemab received accelerated approval from the FDA in January 2023 based on the CLARITY-AD results, making it the first amyloid-targeting therapy to demonstrate meaningful clinical efficacy in a Phase 3 trial.
Trial Details
| Parameter | Value |
|-----------|-------|
| NCT Number | NCT03887455 |
| Phase | Phase 3 |
| Status | Completed |
| Sponsor | Eisai Co., Ltd. |
| Collaborator | Biogen |
| Enrollment | 1,795 patients |
| Duration | 18 months |
| Location | Multiple countries worldwide |
| Drug | Lecanemab (Leqembi) |
| Dosage | 10 mg/kg biweekly IV infusion |
Mechanism of Action
Lecanemab is a monoclonal antibody that selectively binds to and clears soluble amyloid-beta (Aβ) protofibrils, which are believed to be the most toxic form of amyloid plaques in Alzheimer's disease[@lecanemab2023].
Target Specificity
- Primary Target: Aβ protofibrils (soluble oligomeric species)
- Epitope: 3X42 region of Aβ
- Selectivity: 100-fold greater affinity for protofibrils vs monomers
- Mechanism: Fc-mediated microglial phagocytosis
Amyloid Clearance Pathway
This mechanism differs from earlier anti-amyloid antibodies that primarily targeted monomeric Aβ or showed limited brain penetration.
Patient Population
The trial enrolled patients meeting strict criteria:
Inclusion Criteria
- Diagnosis: Mild Cognitive Impairment (MCI) due to AD or mild AD dementia
- Age: 50-90 years
- MMSE score: 22-30
- Amyloid positive: Confirmed by PET scan or CSF biomarkers
- CDR score: 0.5-1.0
Key Characteristics
- Mean age: 71 years
- Approximately 50% female
- diverse ethnic representation
- Early AD stage (MCI or mild dementia)
Endpoints
Primary Endpoint
- Measure: Change from baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) at 18 months
- Result: -0.45 vs placebo (p=0.00005)
Secondary Endpoints
| Endpoint | Result | p-value |
|----------|--------|---------|
| Amyloid PET SUVR | -59.1 Centiloids vs baseline | p<0.001 |
| ADAS-Cog14 | -3.8 vs placebo | p<0.001 |
| ADCS-MCI-ADL | +3.5 vs placebo | p<0.001 |
| ADCOMS | -0.44 vs placebo | p<0.001 |
| CSF p-tau181 | Significant reduction | p<0.001 |
| CSF t-tau | Significant reduction | p<0.001 |
Results
Primary Efficacy
The trial demonstrated significant clinical benefit:
- CDR-SB change: -0.45 vs placebo (27% slowing of progression)
- Statistical significance: p=0.00005 (highly significant)
- Clinical meaningfulness: Slowed decline by approximately 4-5 months equivalent
Amyloid Reduction
- Amyloid PET: 59.1 Centiloid reduction from baseline
- Plaque removal: Near-complete clearance in most patients
- Sustained effect: Maintained throughout 18-month treatment period
Subgroup Analyses
Consistent benefits observed across:
- Age groups (50-90 years)
- APOE ε4 carriers and non-carriers
- MCI and mild AD dementia subgroups
- Various ethnic backgrounds
Adverse Events
| Adverse Event | Lecanemab | Placebo |
|---------------|-----------|---------|
| ARIA-E (edema) | 12.6% | 1.7% |
| ARIA-H (hemorrhage) | 17.3% | 9.0% |
| Infusion reactions | 20.4% | 4.3% |
ARIA Management
Amyloid-related imaging abnormalities (ARIA) are managed through:
- Routine MRI monitoring
- Dose titration at initiation
- Careful patient selection
- Education of clinicians and caregivers
Most ARIA cases were asymptomatic or mild; serious events were rare[@schilling2024].
Clinical Significance
First Demonstrable Disease Modification
CLARITY-AD represents a pivotal moment in Alzheimer's disease research as it demonstrates:
Regulatory Impact
The results led to:
- FDA traditional approval (July 2023)
- Coverage by Medicare in the US
- Inclusion in clinical practice guidelines
Real-World Implications
For patients with early AD[@cummings2023]:
- Earlier diagnosis becomes more critical
- Amyloid testing is essential for treatment selection
- Monitoring protocols must be implemented
- Benefits outweigh risks for appropriate patients
Related Mechanisms and Targets
- [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade-hypothesis)
- [Amyloid-beta](/proteins/amyloid-beta)
- [Anti-Amyloid Immunotherapy](/therapeutics/lecanemab)
- [Amyloid PET Imaging](/biomarkers/amyloid-pet)
Future Directions and Ongoing Studies
Open-Label Extension
The CLARITY-1 (NCT05406091) open-label extension allows patients who completed CLARITY-AD to continue receiving lecanemab, providing:
- Long-term safety data
- Durability of treatment effect
- Insights into extended amyloid clearance
Combination Studies
Research is exploring lecanemab in combination with other therapies:
- Leqembi + AL002: Anti-TREM2 antibody combination
- Leqembi + E2814: Anti-tau antibody combination
- Leqembi + small molecules: Various mechanisms
Prevention Trials
The DIAN-TU-001 trial is evaluating lecanemab in autosomal dominant AD, while the A4 study continues in preclinical AD.
Broader Access Programs
Eisai has implemented:
- Patient assistance programs
- Site expansion for infusion capacity
- Telehealth for monitoring visits
Related Pages
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Lecanemab](/therapeutics/lecanemab)
- [BAN2401 Phase 2b Trial](/clinical-trials/ban2401-201)
- [Donanemab TRAILBLAZER-ALZ](/clinical-trials/donanemab-trailblazer-alz2)
- [A4 Study](/clinical-trials/a4-study)
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | clinical-trials-lecanemab-clarity-ad |
| kg_node_id | None |
| entity_type | clinical |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-b69103dd0b2a |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-lecanemab-clarity-ad'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-clinical-trials-lecanemab-clarity-ad?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Lecanemab CLARITY-AD Trial](http://scidex.ai/artifact/wiki-clinical-trials-lecanemab-clarity-ad)
http://scidex.ai/artifact/wiki-clinical-trials-lecanemab-clarity-ad